A5089167608- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Sphingolipid Metabolism and Signaling
- Neurological Disorders and Treatments
- Inflammasome and immune disorders
- Immunotherapy and Immune Responses
- Vasculitis and related conditions
- IL-33, ST2, and ILC Pathways
- Research on Leishmaniasis Studies
- Infectious Diseases and Tuberculosis
- Polyomavirus and related diseases
- Neurogenesis and neuroplasticity mechanisms
- Sarcoidosis and Beryllium Toxicity Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Parkinson's Disease Mechanisms and Treatments
- vaccines and immunoinformatics approaches
- Virology and Viral Diseases
- Acute Ischemic Stroke Management
- Otitis Media and Relapsing Polychondritis
- Tryptophan and brain disorders
- Systemic Lupus Erythematosus Research
- Cerebrovascular and genetic disorders
- Pharmacological Effects and Toxicity Studies
- Intracerebral and Subarachnoid Hemorrhage Research
- Venous Thromboembolism Diagnosis and Management
University of Lausanne
2019-2023
Laboratory for Biomedical Neurosciences
2022
Kantonsspital Aarau
2022
University of St. Gallen
2022
Hospital Base
2022
University Hospital of Basel
2022
University Hospital of Bern
2022
University Hospital of Lausanne
2015-2021
Sorbonne Université
2021
Institut du Cerveau
2021
<h3>Background and Objective</h3> Depleting CD20<sup>+</sup> B cells is the primary mechanism by which ocrelizumab (OCRE) efficient in persons with multiple sclerosis (pwMS). However, exact role of OCRE on other immune cell subsets directly or indirectly remains elusive. The purpose this study to characterize dynamics peripheral pwMS OCRE. <h3>Methods</h3> We collected blood samples from 38 before onset (T0) at 6 12 months (T6, T12) after initiation. To cover diversity, using mass cytometry...
Endovascular treatment in large artery occlusion stroke reduces disability. However, the impact of anesthesia type on clinical outcomes remains uncertain.We compared consecutive patients Swiss Stroke Registry with anterior circulation receiving endovascular or without general (GA). The primary outcome was disability modified Rankin Scale after 3 months, analyzed ordered logistic regression. Secondary included dependency death (modified score ≥3), National Institutes Health 24 hours,...
Abstract Background Safety of live vaccines in patients treated with immunosuppressive therapies is not well known, resulting contradictory vaccination recommendations. We describe here the first case vaccine-associated measles a patient on natalizumab treatment. Case presentation A young female relapsing-remitting multiple sclerosis treatment received attenuated measles, mumps, and rubella vaccine preparation for change her favour fingolimod, established qualities. Seven days after...
Alemtuzumab is highly effective in relapsing remitting multiple sclerosis (RRMS), but autoimmune adverse events are of concern. In contrast to rare cases immune-mediated cutaneous vasculitis, systemic vasculitis after alemtuzumab has not yet been described. We report the case a 29-year-old man with RRMS who developed fever, auricular chondritis, and life-threatening diffuse alveolar haemorrhage, 12 months alemtuzumab. Antibodies myeloperoxidase appeared 9 were extremely high at time...
In countries where fingolimod is available as first-line therapy without restrictions, we have an opportunity to observe long-term efficacy profile of this drug in treatment-naive patients according their initial disease activity. We retrospectively analysed the data RRMS treated with FTY, focusing on 2 groups: 17 highly active (HA) defined follows: ≥ relapses year before treatment initiation and either 1 Gd-enhancing T1 lesion or a significant increase T2 load from baseline MRI; 37 "not...
The current treated MS population is very different from that of patients in randomized clinical trials. To study the long-term efficacy and tolerance fingolimod (FTY) dimethyl fumarate (DMF), both available as first-line treatment early-treated treatment-naïve patients. Retrospective analysis 75 our prospective registry fulfilling inclusion criteria: FTY or DMF treatment, initiation within 36 months disease onset duration > 12 months. Demographics MRI characteristics at baseline were...
Les nouvelles possibilités thérapeutiques ont changé l’évolution et la prise en charge des patients souffrant de maladies neuro-inflammatoires, permettant dans nombreux cas ralentir progression maladie.
Die neuen Behandlungsmöglichkeiten haben die Entwicklung der neuroinflammatorischen Erkrankungen und Versorgung Patientinnen Patienten verändert. Oft kann dadurch Krankheitsprogression verlangsamt werden.
Isolated chronic granulomatous meningitis remains a diagnostic challenge for the physician. Symptoms are often nonspecific and ancillary tests have low-sensitivity rates, which may delay targeted treatment lead to increased morbidity mortality. Here, we discuss challenges in diagnosing treating patients with by reporting two cases of previously healthy who presented on brain biopsy.
To investigate the viral CD8+ T cell cellular immune response under ocrelizumab.